中国葡萄膜炎患者中Blau综合征的遗传与临床特征
研究依据ACMG指南对3921例葡萄膜炎患者及1003名健康对照的NOD2变异进行致病性分类,8个功能获得性突变被判定为致病性,66例(1.7%)诊断为Blau综合征;Blau综合征患者双侧葡萄膜炎、继发性青光眼、关节炎、关节畸形、皮疹及永久性视力损害比例更高。
要点
- 8个NOD2功能获得性突变被判定为致病性,66例(1.7%)葡萄膜炎患者据此诊断为Blau综合征。
- Blau综合征中全葡萄膜炎占51.5%、前葡萄膜炎占39.4%、后葡萄膜炎占9.1%,74.2%见视网膜微血管炎。
- Blau综合征患者双侧葡萄膜炎(86.4%)、继发性青光眼(47.0%)、关节炎(69.7%)等发生率高于非Blau致病NOD2变异携带者。
核心结论
- Blau综合征的致病NOD2变异限于功能获得性突变,与葡萄膜炎患者关节炎、皮疹、永久性视力丧失及眼部并发症的高风险相关。
研究设计与样本
- 遗传分析与描述性研究,纳入1003名无亲缘关系健康个体和3921例散发性葡萄膜炎患者。
- 对全部健康参与者和551例葡萄膜炎患者行全外显子组测序,对余下3370例葡萄膜炎患者行靶向NOD2重测序。
- 依据ACMG指南对测序发现的NOD2变异进行Blau综合征致病性分类,并比较不同分类级别变异的临床表现。
主要发现
- 8个NOD2功能获得性突变p.R334W、p.R334Q、p.E383K、p.G481D、p.W490S、p.M513T、p.R587C和p.N670K被分类为致病性,66例(1.7%)葡萄膜炎患者据此诊断为Blau综合征。
- 66例Blau综合征中前葡萄膜炎占39.4%、后葡萄膜炎占9.1%、全葡萄膜炎占51.5%,21.2%表现为多灶性脉络膜炎,48.5%有视乳头炎,74.2%经眼底荧光血管造影发现视网膜微血管炎。
- 6个NOD2变异p.P268S、p.R311W、p.R471C、p.A612T、p.R702W和p.V955I被认为对Blau综合征无致病性,见于96例葡萄膜炎患者。
- 双侧葡萄膜炎(86.4%)、继发性青光眼(47.0%)、视网膜前膜(7.6%)、脉络膜新生血管(4.6%)、视网膜萎缩(10.6%)、关节炎(69.7%)、关节畸形(51.5%)和皮疹(40.9%)的发生率在Blau综合征中高于携带非Blau致病NOD2变异的葡萄膜炎患者。
- Blau综合征患者总体永久性最佳矫正视力更差;新发现p.I722L(2例)、p.T476P(1例)、p.T476del(1例)和p.R439H(1例)等罕见NOD2突变。
关键数值与推荐
- NOD2变异按ACMG指南分类,8个功能获得性突变判为致病性,6个变异判为对Blau综合征无致病性。
- Blau综合征诊断依据为携带上述致病性NOD2功能获得性突变。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology call for cautious interpretation of variants as causative of a monogenic disorder by stringent standards. We aimed to reclassify the pathogenicity of nucleotide binding oligomerization domain containing 2 (NOD2) variants according to the ACMG guidelines and to characterize clinical features in patients whose ocular disease might actually be explained by Blau syndrome. DESIGN: Genetic analysis and descriptive study. PARTICIPANTS: A total of 1003 unrelated healthy individuals and 3921 sporadic patients who presented with uveitis. METHODS: Whole-exome sequencing was performed on all healthy participants and 551 patients with uveitis, and targeted NOD2 resequencing was performed on the remaining 3370 patients with uveitis. Pathogenicity for Blau syndrome was classified for NOD2 variants identified by sequencing in study participants according to the ACMG guidelines. Clinical manifestations were compared among NOD2 variants of different levels of classification. MAIN OUTCOME MEASURES: Pathogenicity of variants. RESULTS: Eight NOD2 gain-of-function mutations, p.R334W, p.R334Q, p.E383K, p.G481D, p.W490S, p.M513T, p.R587C, and p.N670K, were classified as pathogenic, and 66 patients (1.7%) with uveitis were diagnosed with Blau syndrome due to these mutations. Of 66 with Blau syndrome, anterior uveitis accounted for 39.4%, posterior uveitis for 9.1%, and panuveitis for 51.5%. A proportion of 21.2% of Blau syndrome presented as multifocal choroiditis, 48.5% had papillitis, and 74.2% showed retinal microvasculitis detected by fundus fluorescein angiography. Six NOD2 variants, p.P268S, p.R311W, p.R471C, p.A612T, p.R702W, and p.V955I, were considered nonpathogenic for Blau syndrome and were identified in 96 patients with uveitis. The incidence of bilateral uveitis (86.4%), secondary glaucoma (47.0%), epiretinal membrane (7.6%), choroidal neovascularization (4.6%), retinal atrophy (10.6%), arthritis (69.7%), joint deformity (51.5%), and skin rash (40.9%) was higher in Blau syndrome than in patients with uveitis carrying non-Blau-causing NOD2 variants. Patients with Blau syndrome permanently experienced overall poorer best-corrected visual acuity. Several rare NOD2 mutations, p.I722L (2 cases), p.T476P (1 case), p.T476del (1 case), and p.R439H (1 case), were newly identified. CONCLUSIONS: Pathogenic NOD2 variants for Blau syndrome were limited to those gain-of-function mutations and were associated with a high risk for arthritis, skin rash, permanent visual loss, and ocular complications in patients with uveitis.
引用
- Zhong Z, Ding J, Su G, et al. Genetic and Clinical Features of Blau Syndrome among Chinese Patients with Uveitis. Ophthalmology. 2022. PMID: 35314268. doi:10.1016/j.ophtha.2022.03.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。